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Abstract We studied the mutation patterns of hepatitis C virus
(HCV) and GB virus C/hepatitis G virus (HGV). Although the
mutation patterns of the two viruses were similar to each other,
they were quite different from that of HIV. In particular, the
similarity of the patterns between HCV or HGV and human
nuclear pseudogenes was statistically significant whereas there
was no similarity between HIV and human nuclear pseudogenes.
This finding suggests that the mutation patterns of HCV and
HGV are similar to the patterns of spontaneous substitution
mutations of human genes, implying that nucleotide analogues
which are effective against HCV and HGV may have a side
effect on the normal cells of humans.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Mutation patterns of various human genes, such as func-
tional genes, pseudogenes, viral oncogenes, and major histo-
compatibility complex genes, have been previously analyzed
by Gojobori et al. [1^3]. They showed the mutation patterns
as a set of 12 kinds of relative substitution frequencies, which
is una¡ected by a bias in base composition [1]. As far as
mutation patterns of viruses are concerned, Moriyama et al.
analyzed the mutation patterns of the human immunode¢-
ciency virus (HIV) genes, using the method of Gojobori et
al. [1], and identi¢ed a speci¢c mutation pattern of HIV [4].
Based on their results of a high frequency of guanosine (G) to
adenosine (A) mutations [4], they inferred that the HIV was
likely to misincorporate thymidine (T) into the DNA genome
during the reverse transcription process. Their inference is
consistent with the high e⁄cacy of 3P-azido-2P,3P-dideoxythy-
midine (AZT), an analogue of T, for HIV infection [5^7].
Hepatitis C virus (HCV) and GB virus C/hepatitis G virus
(HGV) were discovered as the viruses associated with liver
diseases [8^10], and they have been vigorously analyzed by
many investigators world-wide. A large number of nucleotide
sequences related to these viruses has been compiled in the
DNA databases. We obtained 27 HCV 1b and 15 HGV nu-
cleotide sequences encompassing the entire coding region.
From these nucleotide sequences, we estimated the mutation
patterns of HCV and HGV using the method of Gojobori et
al. [1], and attempted to infer an e⁄cient therapy for treating
the infection by these two viruses using nucleoside analogues,
as in the case of HIV. We found that the mutation patterns of
HCV and HGV were similar to each other and that these two
viruses prefer all four transitional mutations. Therefore, ana-
logues of adenine (A), uracil (U), cytosine (C), and guanine
(G) were similarly expected to be e⁄cient in the treatment of
the infection by these two viruses. However, we also found
that mutation patterns of both HCV and HGV were similar
to the patterns of spontaneous substitution mutations of hu-
man genes. This ¢nding would suggest that nucleoside ana-
logues being e¡ective against HCV and HGV may have a side
e¡ect on normal human cells. Our results may provide perti-
nent information for the development of a therapy for the
infection caused by these viruses.
2. Materials and methods
2.1. HCV and HGV nucleotide sequence data studied
The nucleotide sequence data for 27 HCV 1b strains and an HCV
1a strain (as shown in Fig. 1) and 15 HGV strains (as shown in Fig.
2), encompassing the entire coding region, were collected from the
DNA databases (DDBJ/EMBL/GenBank).
2.2. Construction of phylogenetic trees for HCV and HGV strains
The nucleotide sequence alignments were made for the 27 HCV 1b
strains with an HCV 1a strain, and for the 15 HGV strains, using the
entire coding region. The computer program CLUSTAL W was used
to produce sequence alignments [11], and the results were checked by
eye. The phylogenetic trees were constructed for both the HCV and
HGV strains, by the neighbor-joining method [12], with the evolu-
tionary distances estimated by the 6-parameter method [13]. These
analyses were performed on the molecular evolutionary software sys-
tem, ODEN version 1.1 [14].
As shown on the Web site of the HCV database (http://s2as02.ge-
nes.nig.ac.jp), HCV 1b and 1a strains made separate clusters in the
phylogenetic tree for HCV strains. Therefore, we regarded an HCV 1a
strain, the HCV-1, as an outgroup sequence in the phylogenetic tree
for the 27 HCV 1b strains. Concerning HGV strains, African-type
strains such as GBV-C reported by Simons et al. has been shown to
diverge ¢rst from other HGV strains in the phylogenetic analyses for
HGV strains [9,15]. Therefore, we regarded the GBV-C as an out-
group sequence in the phylogenetic tree for the remaining 14 HGV
strains.
2.3. Analyses of mutation patterns for the 27 HCV 1b and 14 HGV
strains
The mutation patterns for the 27 HCV 1b and 14 HGV strains were
estimated by the method of Gojobori et al. [1]. In the phylogenetic
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trees for HCV and HGV strains, the ancestral sequence was inferred
at every node by the maximum parsimony method [3]. Then, the
numbers for the 12 kinds of mutations, namely, A to U, A to C, A
to G, U to A, and so on, were counted for each tree. If the nucleotide
at a node had not been determined uniquely, we ignored the muta-
tions that must have occurred on the branches connected with that
node. To obtain the relative substitution frequencies among four nu-
cleotides, the numbers of mutations were standardized by the base
compositions [1]. The relative substitution frequency indicates the
substitution frequency from a particular nucleotide to another in a
hypothetical sequence of 100 nucleotides with equal amounts of each
nucleotide base (25A, 25U, 25C, 25G). This value is more useful than
the raw frequency of nucleotide substitutions, because it is free from
the bias in the base compositions in actual sequences [1]. The muta-
tion patterns were estimated at the 1st and 2nd positions, and the 3rd
position of the codons, respectively.
2.4. Comparisons among the mutation patterns
By computing the correlation coe⁄cients between the sets of rela-
tive substitution frequencies, the mutation patterns for HCV and
HGV were compared with one another. In this comparative study,
we also included the mutation patterns for the HIV genes, human
nuclear pseudogenes, and human functional genes, which were ob-
tained from the literature [1,4].
3. Results
3.1. Mutation patterns of HCV and HGV strains
From the analysis of approximately 250 000 nucleotides of
the 27 HCV 1b strains, encompassing the entire coding re-
gions, we detected 8960 mutations at all positions of the co-
dons, out of which 2664 and 6296 were at the 1st and 2nd
positions, and at the 3rd position of the codons, respectively.
From the analysis of approximately 130 000 nucleotides of the
14 HGV strains, encompassing the entire coding regions, we
detected 6653 mutations at all positions of the codons, out of
which 1027, and 5626 were at the 1st and 2nd positions, and
at the 3rd position of the codons, respectively. For the HCV
strains, in 386 mutations of these mutations, which particular
nucleotide mutated to another could not be uniquely deter-
mined. For the HGV strains, 1043 mutations could not be
uniquely determined. We excluded these mutations from our
analysis and computed the relative substitution frequencies in
the entire coding region of HCV and HGV from the remain-
ing 8574 and 5610 mutations, at the 1st and 2nd positions,
and at the 3rd position of the codons, respectively. Table 1
shows the relative substitution frequencies at the 1st and 2nd
positions, and at the 3rd position of the codons for the 27
HVC 1b and 14 HGV strains. In HCV 1b strains, the fre-
Fig. 1. A phylogenetic tree of the entire coding region of 22 HCV
1b strains with an HCV 1a strain as the outgroup sequence. The se-
quence data were collected from the DNA databases (DDBJ/
EMBL/GenBank). The following are the accession numbers of the
HCV strains analyzed: HCV-1: M62321, HCV-JS: D85516,
HPCJ491: D10750, HPCJ483: D13558, HPCJTA: D11168,
HPCJTB: D11355, HCV-J: D90208, HCV-N: D63857,
HPCHUMR: M58335, *HCV-N: S62220, HPCRNA: D10934,
HCU01214: U01214, HPCPP: D30613, HPCHCPO: D45172,
HPCK1S3: D50484, HPCK1R3: D50482, HPCK1S2: D50485,
HPCK1R2: D50481, HPCK1S1: D50483, HPCK1R1: D50480,
HCVJK1G: X61596, and HPCGENANTI: M84754, HCU45476:
U45476, HPCUNKCDS: M96362, HCU16362: U16362,
HPCJRNA: D14484, TMORF: D89872. The tree was constructed
by the neighbor-joining method based on the numbers of nucleotide
substitutions estimated by the 6-parameter method. The root of the
tree was determined at the midpoint of the tree between the 27
HCV 1b strains and an HCV 1a strain. The most recent ancestor
for HCV 1b strains is represented by the ¢lled circle. We continued
to infer the ancestral nucleotide at every node of the phylogenetic
tree in each nucleotide position of the entire coding region of these
HCV 1b strains. The numbers of the 12 kinds of mutations in the
entire coding region of 27 HCV 1b strains were determined from
the tree topology. Subsequently, we computed the relative substitu-
tion frequencies from the numbers of the 12 kinds of mutations,
corrected by the nucleotide compositions of the studied strains. The
scale bar indicates the number of nucleotide substitutions per site.
Table 1
Mutation patterns for HCV 1b and HGV
1st and 2nd positions 3rd position All positions
HCV 1b HGV HCV 1b HGV HCV 1b HGV
A U 5.0 2.8 1.9 6.7 2.7 4.7
C 4.9 8.9 2.0 4.4 2.7 4.5
G 20.2 9.6 24.3 16.2 19.7 11.9
U A 3.5 3.3 1.6 5.1 2.1 4.5
C 15.4 23.3 28.8 19.4 22.9 19.1
G 2.4 2.7 1.8 5.0 1.9 4.3
C A 4.7 9.6 1.3 3.2 2.5 4.8
U 16.5 26.0 19.7 18.0 22.6 22.5
G 5.8 2.3 1.5 3.6 2.9 4.0
G A 15.3 6.8 14.2 10.6 15.8 11.3
U 2.0 1.6 1.4 4.5 1.7 4.6
C 4.4 3.3 1.6 3.5 2.6 3.9
Transition 67.4 65.7 87.0 64.2 81.0 64.8
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quencies of transitions, including A to G, G to A, U to C, and
C to U, were high at both the 1st and 2nd positions and at the
3rd position of the codons. The total frequency of the four
transitions of HCV at the 3rd position was 87.0%. In HGV
strains, the frequencies of transitions, including A to G, G to
A, U to C, and C to U, were high at the 3rd position of the
codons.
3.2. Correlation coe⁄cients among mutation patterns of various
genes
To quantify the similarities in mutation patterns between
di¡erent genes, we calculated the correlation coe⁄cients and
P values between the di¡erent sets of relative substitution
frequencies of the genes (Table 2).
The correlation coe⁄cients between the frequencies at the
1st and 2nd positions and those at the 3rd position of the
codons were high in both HCV and HGV strains. The coef-
¢cient for HCV was 0.935 (P6 0.0001), and that for HGV
was 0.833 (P = 0.0003). The patterns at the 1st and 2nd posi-
tions and at the 3rd position were signi¢cantly similar to each
other in both HCV and HGV, although the patterns at the 1st
and 2nd positions should be skewed by selective forces and
the patterns at the 3rd position of the codons should be close
to the pattern of spontaneous substitution mutation.
Correlation coe⁄cients between HCV and HGV were very
high, at both the 3rd position and all positions. The coe⁄cient
at the 3rd position was 0.974 (P6 0.0001) and was 0.952
(P6 0.0001) at all positions. Since the patterns at the 3rd
position of the codons should be close to the pattern of spon-
taneous substitution mutations [4], the spontaneous substitu-
tion patterns of HCV and HGV were similar to each other.
The lowest value of the correlation coe⁄cients among the
patterns of HCV and HGV was found between the patterns
of HCV and HGV at the 1st and 2nd positions. In this case,
the correlation coe⁄cient was 0.690 (P = 0.011).
The mutation patterns for HIV genomes were analyzed us-
ing the phylogenetic tree by Moriyama et al. [4]. We, then,
included the mutation pattern for HIV in this comparative
analysis. The correlation coe⁄cients between the patterns of
HIV genomes were in the range from 0.659 (P = 0.078) to
0.909 (P6 0.0001), and the patterns between HIV genomes
were correlated to one another. Next, we compared the muta-
tion pattern of HCV and HGV with that of HIV. The corre-
lation coe⁄cients in the patterns between the HCV and HIV
genomes ranged from 0.471 (P = 0.1249) to 0.724 (P = 0.0059).
The correlation coe⁄cients in the patterns between the HGV
and HIV genomes ranged from 0.111 (P = 0.7390) to 0.531
(P = 0.0757). These results indicate that the patterns of HCV
and HGV correlated to each other, more than those of HCV
and HIV, or those of HGV and HIV, since the correlation
coe⁄cients in the patterns between the HCV and HGV ranged
from 0.690 (P = 0.011) to 0.976 (P6 0.0001).
Moreover, we included the mutation patterns of human
nuclear pseudogenes and functional genes reported previously
[1], in this study. The mutation pattern of human nuclear
pseudogene can be thought of as the pattern of spontaneous
substitution mutation of the human gene, because the pseu-
dogenes do not code for any functional proteins and thus can
accumulate any kind of mutational change. The correlation
coe⁄cient in the patterns between human nuclear pseudo-
genes and functional genes was 0.496 (P = 0.1026), and then,
the selective force to functional genes was suggested. We com-
pared the patterns of HCV, HGV, and HIV with those of
human genes. The correlation coe⁄cients in the patterns be-
tween human nuclear pseudogenes and HCV ranged from
0.562 (P = 0.0563) to 0.718 (P = 0.0067). The correlation coef-
¢cients in the pattern between human nuclear pseudogene and
HGV ranged from 0.626 (P = 0.0276) to 0.755 (P = 0.0032).
The correlation coe⁄cients in the pattern between human
nuclear pseudogenes and HIV ranged from 0.453
(P = 0.1430) to 0.660 (P = 0.0174). These observations indicate
that the correlations between the patterns of HCV of HGV
and human nuclear pseudogenes were stronger than the cor-
relation between those of HIV and human nuclear pseudo-
genes. Therefore, the mutation patterns of HCV and HGV
were similar to the pattern of spontaneous substitution muta-
tion of the human genome.
4. Discussion
In functional genes, the mutation patterns at the 3rd posi-
tion of the codons can re£ect, to some extent, the patterns of
spontaneous substitution mutations, since the mutations at
the 3rd position among such genes are mostly free from func-
Fig. 2. A phylogenetic tree of the entire coding region of 15 HGV
strains. The following are the accession numbers of the HGV strains
analyzed: GBV-C: U36380, HGU44402: U44402, HGU45966:
U45966, HGV-IW: D87255, G05BD: AB003292, CG01BD:
AB003289, CG07BD: AB003290, G13HC: AB003293, BG1HC:
AB003288, T110: D90600, T230: D90601, GBV-C(EA): U63715,
HGVC964: U75356, GS185: D87262, GS193: D87263. The tree
was constructed by the neighbor-joining method based on the num-
bers of nucleotide substitutions estimated by the 6-parameter meth-
od. Tanaka et al. demonstrated that the HGV originated from Afri-
can-type strains such as GBV-C (accession number: U36380)
reported by Simons et al. [9,15]. Therefore, we constructed the phy-
logenetic tree of 14 HGV strains with GBV-C as the outgroup se-
quence. The root of the tree was determined at the midpoint of the
tree between the 14 HGV strains and GBV-C, and we thought that
the node was the ancestral nucleotide sequence of these 14 HGV
strains (represented by the ¢lled circle). We continued to infer the
ancestral nucleotide at every node of the phylogenetic tree in each
nucleotide position of the entire coding region of these HGV
strains. The numbers of 12 kinds of mutations in the entire coding
region of 14 HGV strains were inferred from the tree topology.
Subsequently, we computed the relative substitution frequencies
from the numbers of the 12 kinds of mutations, corrected by the
nucleotide compositions of the studied strains. The scale bar indi-
cates the number of nucleotide substitutions per site.
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tional constraints [4]. We have shown that the mutation pat-
terns of HCV and HGV were similar to each other, especially,
at the 3rd codon position. Therefore, the patterns of sponta-
neous substitution mutations for HCV and HGV were sug-
gested to be similar. In the case of viruses, it is believed that
the incidence of mutations is mainly related to the ¢delity of
replicase [16^18]; thus, the characteristics of the virus repli-
case may re£ect the patterns of spontaneous substitution mu-
tation [4]. As far as HCV and HGV were concerned, they are
replicated by their own RNA-dependent RNA polymerases
[19,20]. Therefore, the similarity of the mutation patterns be-
tween HCV and HGV at the 3rd codon position, character-
ized by a high frequency of transitions, may imply that the
natures of RNA-dependent RNA polymerase of the two vi-
ruses are similar to each other. HCV and HGV were reported
to be evolutionarily related to each other and to belong to the
Flaviviridae family [9,10]. Both are positive-strand RNA vi-
ruses with a similar genomic organization [20]. This may be
the reason why HCV and HGV have common mutation pat-
terns that re£ect the characteristics of each RNA-dependent
RNA polymerase.
Nucleoside analogues are known to inhibit replicase of ge-
nomes as substrate competitors. Replication or mutation rate
of HCV [21,22], HGV [23], and HIV genomes were reported
to be higher than that of the human genome [24,25]. There-
fore, nucleoside analogues are supposed to inhibit the repli-
case of these viruses more e⁄ciently than DNA polymerase of
the host’s cells. In the therapy for HIV infection, AZT is more
e¡ective than other nucleoside analogues, and is the most
appropriate agent among nucleoside analogues for combina-
tion therapy against HIV infection [5,6,26]. Moriyama et al.
estimated the mutation patterns of HIV and suggested that a
high incidence of G to A mutation is one of the reasons for
the greater e⁄cacy of AZT, when compared with other nu-
cleoside analogues. During HIV replication, normally, G in
HIV RNA is replicated to complementary C in DNA by
reverse transcriptase (RT), and the C is replicated to comple-
mentary G in a new virus particle by DNA-dependent DNA
polymerase of the host. In the G to A mutation, G is sup-
posed to be replicated to incorrect T in DNA by RT, since the
high incidence of mutations of HIV is due mainly to the low
¢delity of RT. Therefore, a high incidence of G to A muta-
tions implies that incorrect T is more easily misincorporated
into DNA by RT. Thus, Moriyama et al. explained why AZT,
an analogue of T, is more e¡ective than other analogues.
Using nucleoside analogues from our observations, we at-
tempted to infer an e⁄cient therapy for HCV and HGV in-
fection. In the analysis of the mutation patterns of HCV and
HGV, we found that these two viruses prefer to mutate by all
four transitional patterns (Table 1). Therefore, analogues of
A, U, C, and G were equally incorporated into their next
generation during the replication process, and were expected
to be e⁄cient in the inhibition of the replication of these two
viruses. However, the mutation patterns of HCV and HGV
were similar to the patterns of spontaneous substitution mu-
tations of human genes. This ¢nding suggests that nucleoside
analogues e⁄cient for inhibiting the replication of HCV or
HGV could also inhibit the replication of human genes, and
that severe side e¡ects may result as a consequence.
Although HCV and HGV had a similar mutation pattern,
as described above, humans infected by these viruses show
di¡erent clinical manifestations. HCV has been a causative
agent of chronic liver disease [27] and is associated etiologi-
cally with hepatocellular carcinoma [28]. In regard to the
therapy for chronic hepatitis C, the current standard therapy
using interferon is rather unsatisfactory [29^31]. Therefore,
the search for additional therapies needs to be pursued. On
the other hand, the association of HGV infection with liver
Table 2
Correlation coe⁄cient of mutation patterns for various genes
HCV 1st
and 2nda
HCV
3rdb
HCV
allc
HGV 1st
and 2nda
HGV
3rdb
HGV
allc
HIV
env 3rdb
HIV
env allc
HIV
gag 3rdb
HIV
gag allc
Human
nuclear
pseudogene
HCV 3rdb 0.935
(6 0.0001)
HCV allc 0.957
(6 0.0001)
0.976
(6 0.0001)
HGV 1st and 2nda 0.690
(0.011)
0.783
(0.0016)
0.828
(0.0004)
HGV 3rdb 0.907
(6 0.0001)
0.974
(6 0.0001)
0.976
(6 0.0001)
0.833
(0.0003)
HGV allc 0.839
(0.0003)
0.896
(6 0.0001)
0.952
(6 0.0001)
0.927
(6 0.0001)
0.948
(6 0.0001)
HIV env 3rdb 0.615
(0.314)
0.471
(0.1249)
0.505
(0.0956)
0.111
(0.7390)
0.355
(0.2658)
0.308
(0.3401)
HIV env allc 0.724
(0.0059)
0.534
(0.0738)
0.550
(0.0634)
0.174
(0.5985)
0.411
(0.1895)
0.320
(0.3201)
0.909
(6 0.0001)
HIV gag 3rdb 0.680
(0.0129)
0.574
(0.0500)
0.642
(0.0225)
0.285
(0.3790)
0.531
(0.0757)
0.520
(0.0837)
0.887
(6 0.0001)
0.756
(0.0031)
HIV gag allc 0.747
(0.0037)
0.803
(0.0009)
0.788
(0.0014)
0.503
(0.0967)
0.734
(0.0049)
0.674
(0.0142)
0.764
(0.0025)
0.659
(0.0178)
0.856
(0.0001)
Human nuclear
pseudogene
0.709
(0.0079)
0.562
(0.0563)
0.718
(0.0067)
0.628
(0.0267)
0.626
(0.0276)
0.755
(0.0032)
0.462
(0.1337)
0.456
(0.1395)
0.660
(0.0174)
0.453
(0.1430)
Human functional
genes
0.462
(0.1333)
0.199
(0.5411)
0.298
(0.3573)
30.028
(0.9340)
0.103
(0.7560)
0.144
(0.6643)
0.812
(0.0007)
0.803
(0.0009)
0.636
(0.0243)
0.373
(0.2394)
0.496 (0.1026)
The values whose P values are less than 0.001 are underlined.
a1st and 2nd: 1st and 2nd positions.
b3rd: 3rd position.
call : all positions
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disease has recently become doubtful [32,33], although HGV
has been identi¢ed as a new virus that causes hepatitis [9,10].
HGV may be an innocent by-stander virus and a therapy for
HGV infection may not be indicated at all. The bene¢ts of a
therapy for HCV or HGV infection, using nucleoside ana-
logues, must be weighed carefully, considering the side e¡ects
of nucleoside analogues and the pathogenesis of these two
viruses. Therefore, it is imperative that further studies in
this area be conducted.
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